Aktienanalyse zu Globus Medical Inc (GMED)GMEDGlobus Medical Inc

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Globus Medical Inc is currently trading at $76.71, which is below the average analyst price target of $85 from RBC Capital. The stock has a forward P/E ratio of 13.87, indicating it is relatively undervalued compared to its earnings potential. However, insider selling has increased by 389.20% recently, which raises concerns about the stock's short-term outlook. Therefore, while the long-term growth potential remains, the current market sentiment and insider activity suggest a cautious approach, leading to a hold recommendation.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.